13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001974915
Total reported value
$4.3B
$4.3B
63 檔
11.2%
In Q1 2025, Vestal Point Capital, LP's U.S. equity holdings reached a combined market value of $4.3B, distributed across 63 disclosed stock positions.
During Q1 2025, Vestal Point Capital, LP's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ACLXGBX | Arcellx Inc | Stock-Other | 11.19% | — | +402.68% | |
| 2 | CYTK | Cytokinetics Inc | Stock-Healthcare | 7.43% | -0.55% | EXIT | |
| 3 | INSM | Insmed Inc | Stock-Healthcare | 5.86% | +0.62% | NEW | |
| 4 | NUVL | Nuvalent Inc-a | Stock-Other | 5.44% | -1.38% | EXIT | |
| 5 | VERA | Vera Therapeutics Inc | Stock-Other | 4.29% | -1.54% | EXIT | |
| 6 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 3.92% | -1.04% | EXIT | |
| 7 | QURE | uniQure N.V. | Stock-Other | 3.63% | +0.85% | +58.43% | |
| 8 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 3.59% | — | — | |
| 9 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 3.11% | -0.05% | +60.49% | |
| 10 | SRRK | Scholar Rock Holding CORP | Stock-Other | 2.98% | -1.82% | EXIT | |
| 11 | BCAX | Bicara Therapeutics Inc | Stock-Other | 2.58% | +0.62% | +290.00% | |
| 12 | GERN | Geron CORP | Stock-Other | 2.50% | -0.11% | EXIT | |
| 13 | AM6 | Amicus Therapeutics Inc | Stock-Other | 2.49% | — | +27.61% | |
| 14 | ✓ | Immatics NV | Stock-Other | 2.32% | -0.24% | +14.62% | |
| 15 | GPCR | Structure Therapeutics Inc | Stock-Other | 2.21% | — | +3.71% | |
| 16 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 2.20% | — | +58.15% | |
| 17 | SVRA | Savara Inc | Stock-Other | 2.18% | -0.01% | +2.09% | |
| 18 | TYRA | Tyra Biosciences Inc | Stock-Other | 1.91% | -0.06% | EXIT | |
| 19 | DHR | Danaher CORP | Stock-Healthcare | 1.83% | — | — | |
| 20 | URGN | UroGen Pharma Ltd. | Stock-Other | 1.70% | -0.07% | EXIT | |
| 21 | ASND | Ascendis Pharma A/S | Stock-Other | 1.67% | -2.40% | EXIT | |
| 22 | CATBUSD | Astria Therapeutics Inc | Stock-Other | 1.59% | — | — | |
| 23 | DAWNGBX | Day One Biopharmaceuticals I | Stock-Other | 1.47% | — | +80.43% | |
| 24 | DYN | Dyne Therapeutics Inc | Stock-Other | 1.34% | -0.28% | — | |
| 25 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 1.29% | — | -66.67% | |
| 26 | LQDA | Liquidia CORP | Stock-Other | 1.29% | — | -30.26% | |
| 27 | COGT | Cogent Biosciences Inc | Stock-Other | 1.28% | -1.32% | EXIT | |
| 28 | ✓ | Establishment Labs Holdings In | Stock-Other | 1.26% | — | +44.40% | |
| 29 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 1.21% | — | -45.93% | |
| 30 | PRGO | Perrigo Company plc | Stock-Healthcare | 1.18% | — | +56.71% | |
| 31 | GEHC | GE Healthcare Technology | Stock-Healthcare | 1.18% | +0.17% | — | |
| 32 | ✓ | Nyxoah S A | Stock-Other | 1.16% | -0.04% | -20.70% | |
| 33 | GMED | Globus Medical Inc - A | Stock-Healthcare | 1.05% | +0.10% | -38.46% | |
| 34 | NRIX | Nurix Therapeutics Inc | Stock-Other | 0.95% | +1.74% | +132.07% | |
| 35 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 0.91% | — | -20.00% | |
| 36 | BRKR | Bruker CORP | Stock-Healthcare | 0.89% | — | — | |
| 37 | CDTX | Cidara Therapeutics Inc | Stock-Other | 0.78% | — | — | |
| 38 | BDTX | Black Diamond Therapeutics I | Stock-Other | 0.62% | — | — | |
| 39 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 0.56% | — | — | |
| 40 | SLDB | Solid Biosciences Inc | Stock-Other | 0.46% | -0.51% | -38.47% | |
| 41 | IMVT | Immunovant Inc | Stock-Other | 0.43% | — | +677.78% | |
| 42 | ZYME | Zymeworks Inc | Stock-Other | 0.43% | — | +170.27% | |
| 43 | APLT | Applied Therapeutics Inc | Stock-Other | 0.40% | — | — | |
| 44 | 2662247D | Iteos Therapeutics Inc | Stock-Other | 0.38% | — | — | |
| 45 | LKFT | Lakefront Biotherapeutic-adr | Stock-Other | 0.36% | — | +11.11% | |
| 46 | VYGR | Voyager Therapeutics Inc | Stock-Other | 0.30% | -0.11% | +1.58% | |
| 47 | LXEO | Lexeo Therapeutics Inc | Stock-Other | 0.28% | -0.25% | -5.31% | |
| 48 | KNSA | Kiniksa Pharmaceuticals International, plc | Stock-Other | 0.27% | — | — | |
| 49 | CLDX | Celldex Therapeutics Inc | Stock-Other | 0.26% | -1.09% | EXIT | |
| 50 | OKUR | Onkure Therapeutics Inc-a | Stock-Other | 0.19% | -0.02% | — |
According to official SEC Form 13F filings, Vestal Point Capital, LP reported a total U.S. public equity portfolio value of $4.3B across 63 disclosed positions in Q1 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ACLXGBX, CYTK, INSM) accounted for 11.2% of total reported equity market value during Q1 2025.
During Q1 2025, Vestal Point Capital, LP's top holdings by market value included ACLXGBX (11.2%)、CYTK (7.4%)、INSM (5.9%). The largest single position, ACLXGBX, represented 11.2% of total portfolio value.
In Q1 2025, Vestal Point Capital, LP made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.